NCT01407133

Brief Summary

The objective of the investigators study is to assess conventional repetitive transcranial magnetic stimulation (rTMS) in patients with chronic severe tinnitus. A randomized, double-blind, sham-controlled procedure, with four increasing levels of magnetic "pseudo-dose" has been designed, in order to characterize the effectiveness of rTMS while controlling its safety and tolerability. By combining various rTMS protocols with a twelve-month follow-up, and using an effect modeling, the study aims at: (i) specify the effective values of rTMS parameters, with an adequate tolerance; (ii) determine the expected benefit and the persistence of effect; (iii) assess the practical feasibility of this kind of therapeutic management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started May 2005

Longer than P75 for phase_1

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2005

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

July 26, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 2, 2011

Completed
Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

4.3 years

First QC Date

July 26, 2011

Last Update Submit

December 13, 2025

Conditions

Keywords

Neuro-otologyChronic tinnitusSensory disabilityRepetitive transcranial magnetic stimulationDose escalation

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in tinnitus perception, as measured over time using a visual analog rating scale (subjective loudness of tinnitus)

    The time between enrollment and rTMS intervention will vary from one subject to another (expected average of 4 months); depending on the protocol, the end of the intervention corresponds to the end of week 1, 4, 5 or 20 (first day of rTMS as reference)

    At subject enrollment; daily for 2 weeks before the intervention; before and after each rTMS session, once at the end of each week and at the end of intervention; during follow-up: twice a week for 6 months, and 1 year after the end of intervention

Secondary Outcomes (10)

  • Tolerance of rTMS, evaluated through a semi-structured interview on specific and nonspecific adverse events

    After the first rTMS session; before and after each following session and at the end of intervention period; 1, 4 or 5, and 20 weeks after the start of intervention; 1, 3, 6 months and 1 year after the end of intervention

  • Auditory status, evaluated through tonal audiometry (pure-tone average)

    At subject enrollment; before the first rTMS session and after the last rTMS session (for all types of protocols), and every five sessions of rTMS (for long protocols)

  • Change in severity of tinnitus, measured through a multidimensional self-questionnaire: Subjective Tinnitus Severity Scale (STSS)

    At subject enrollment; before the first rTMS session, in the middle and at the end of intervention period; 1, 4 or 5, and 20 weeks after the start of intervention; 1, 3, 6 months and 1 year after the end of intervention

  • Change in handicap related to tinnitus, measured through a multidimensional self-questionnaire: Tinnitus Handicap Questionnaire (THQ)

    At subject enrollment; at the beginning, in the middle and at the end of rTMS intervention period; 1, 4 or 5, and 20 weeks after the start of intervention; 1, 3, 6 months and 1 year after the end of intervention

  • Change in hyperacusis, measured through a multidimensional self-questionnaire: Auditory Hypersensitivity Questionnaire

    At subject enrollment; at the beginning, in the middle and at the end of rTMS intervention period; 1, 4 or 5, and 20 weeks after the start of intervention; 1, 3, 6 months and 1 year after the end of intervention

  • +5 more secondary outcomes

Study Arms (2)

Active rTMS

EXPERIMENTAL

48 subjects will receive active temporal rTMS, applied with the following combined parameters: * intensity: 100% of resting motor threshold * stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz) * number of stimulations per session: 300, 900 or 1800 per session * number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week) * total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions).

Device: transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)

Sham rTMS

SHAM COMPARATOR

16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)

Device: Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)

Interventions

The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic "pseudo-dose" on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months.

Also known as: Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)
Active rTMS

Same sound level as active rTMS, but magnetic field strongly attenuated

Also known as: Medtronic © MagPro X100 (with MagOption) stimulator and Placebo Butterfly Coil MCF-P-B65 (shielded figure-8 coil with fluid cooling)
Sham rTMS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women between the ages of 18 and 75 years old;
  • Adequate medical condition (ASA P1 or P2 in Physical Status Classification System);
  • Disabling tinnitus (STSS \> 8/16 or THQ \> 50%), with the following characteristics: continuous, subjective, non-pulsatile; unilateral (or bilateral with unilateral predominance), chronic (duration for at least one year), refractory for usual treatments taken for at least six months;
  • Naive regarding TMS;
  • Able to provide informed consent.

You may not qualify if:

  • Objective tinnitus or tinnitus with treatable cause;
  • Presence of intracranial or intraocular ferromagnetic materiel or particles (with the exception of dental fillings and MRI-compatible stapedectomy prosthesis);
  • Cardiac pacemaker or other electronic implants (including cochlear implant);
  • Serious heart disease or other unstable major medical condition;
  • Personal history of central nervous system disorder, head injury, stroke or seizures (including childhood febrile seizures);
  • Familial history of epilepsy;
  • Concomitant medication with antidepressants and antipsychotics;
  • Possibility of pregnancy;
  • Known claustrophobia;
  • Others known contraindications to rTMS or brain MRI;
  • Refusal to be informed about the results of anatomical MRI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Département d'ORL et de Chirurgie Cervico-Maxillo-Faciale, Hôpital Edouard Herriot

Lyon, 69437, France

Location

Service d'Audiologie et Explorations Orofaciales, Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France

Location

Service d'Oto-Rhino-Laryngologie, Centre Hospitalier Lyon-Sud

Pierre-Bénite, 69495, France

Location

Related Publications (3)

  • Tringali S, Perrot X, Collet L, Moulin A. Repetitive transcranial magnetic stimulation (rTMS) noise: a relevance for tinnitus treatment? Brain Stimul. 2012 Oct;5(4):655-6. doi: 10.1016/j.brs.2011.10.006. Epub 2012 Feb 22. No abstract available.

  • Tringali S, Perrot X, Collet L, Moulin A. Repetitive transcranial magnetic stimulation noise levels: methodological implications for tinnitus treatment. Otol Neurotol. 2012 Sep;33(7):1156-60. doi: 10.1097/MAO.0b013e318263d37d.

  • Tringali S, Perrot X, Collet L, Moulin A. Repetitive transcranial magnetic stimulation: hearing safety considerations. Brain Stimul. 2012 Jul;5(3):354-363. doi: 10.1016/j.brs.2011.06.005. Epub 2011 Jul 26.

Study Officials

  • Xavier PERROT, MD, PhD

    Service d'Audiologie et Explorations Orofaciales (Pr. COLLET) - Centre Hospitalier Lyon Sud - Hospices Civils de Lyon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2011

First Posted

August 2, 2011

Study Start

May 1, 2005

Primary Completion

September 1, 2009

Study Completion

September 1, 2009

Last Updated

December 19, 2025

Record last verified: 2025-12

Locations